COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Other Events
Item8.01
| Other Events |
On April25, 2017, Coherus BioSciences, Inc. issued a press
release reporting completion of the initial phases of the
Biologics Price Competition and Innovation Act patent exchange
procedure with Amgen Inc. for CHS-1701, its pegfilgrastim
(Neulasta) biosimilar candidate. A copy of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated by reference into this Item8.01.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
Exhibit No. |
Description |
|
| 99.1 | Press release dated April 25, 2017. |
About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS)
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs). COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Recent Trading Information
COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) closed its last trading session up +1.10 at 20.15 with 487,465 shares trading hands.